CLINICAL STUDY OF EFFECT OF LOW DOSE ATROPINE DROPS ON PROGRESSION OF MYOPIA IN CHILDREN

Abstract

Introduction: Myopia, a prevalent refractive disorder, affects 22.9% of the global population, potentially affecting half by 2050. Risk factors include insufficient outdoor time and repetitive tasks. Early interventions are crucial. Aims: The study examines the impact of daily atropine drop doses on the progression of myopia in children, their effects on axial length and macular thickness, and the reverse effect of local atropine drops. Methodology: The study examined the impact of 0.01% atropine eye drops on myopia progression in 66 children aged 6-15 at the Krishna Institute of Medical Sciences Deemed University, Karad, India. Participants were assessed for symptoms like glare, photophobia, and reading difficulties, and adverse effects documented. Results: The study analyzed 132 eligible children aged 7-15, revealing non-normal distribution and needing further statistical correlations. Results showed a significant correlation between low dose atropine drops and keratometric values at 12 and 18 months, but no significant changes in axial length or macular thickness. Discussion: A study in India found that low-dose atropine significantly impacts myopia progression in 66 children aged 6-15. The study found no significant changes in axial length or macular thickness over three follow-ups, suggesting 0.01% atropine effectively prevents myopia advancement. Over a three-year period, it is more effective in slowing myopia progression with minimal adverse effects. Conclusion: Myopia, caused by genes and environment, can be treated with orthokeratology, atropine, or soft multifocal contact lenses, with low-dose atropine slowing development but requiring further research.